Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more
Roivant Sciences operates as a clinical-stage biopharmaceutical holding company built around a "hub-and-spoke" model, with subsidiary programs concentrated in immunology and inflammation. Its strategic advantage lies in a late-stage pipeline spanning three potential first-in-class or best-in-class mechanisms: brepocitinib, a dual TYK2/JAK1 inhibitor (tyrosine kinase 2 and Janus kinase 1, enzymes involved in immune signaling); IMVT-1402, a next-generation FcRn inhibitor targeting IgG (immunoglobulin G)-mediated autoimmune diseases; and mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator for pulmonary disease.
Rather than relying on a single asset, Roivant's positioning emphasizes multiple "pipeline-in-a-product" opportunities, each with several potential blockbuster indications. Management has guided toward three or more launches, four or more new drug application (NDA) and biologics license application (BLA) filings, and more than eight pivotal readouts over the next three years. This breadth reduces single-asset dependency but also concentrates execution risk in clinical data quality and commercial ramp. The company's substantial cash position and ownership stakes in subsidiaries such as Immunovant and Priovant give it both funding durability and capital-allocation optionality.
The most immediate catalyst is the U.S. launch of LISRAYA in dermatomyositis, a rare autoimmune muscle disease. Because no novel therapy has launched in this indication for years, early prescription, reimbursement, and coverage trends will be closely watched, though management has cautioned that early launch metrics carry wide error bars.
Beyond the launch, several data events could materially shift sentiment. Phase 3 topline data for brepocitinib in non-infectious uveitis, a leading cause of blindness, is expected in the second half of 2026 and could support a second registered indication. IMVT-1402's randomized withdrawal data in difficult-to-treat rheumatoid arthritis will clarify whether deep open-label responses translate into a viable registrational path. Mosliciguat's Phase 2 readout in PH-ILD represents a large, underserved commercial opportunity with limited competition.
Analyst activity reflects growing optimism. Recent actions include Citi raising its price target to $56 and TD Cowen to $62, alongside reiterated Buy ratings from H.C. Wainwright, Guggenheim, and others. The consensus recommendation profile skews heavily toward "Strong Buy," with the average target having trended upward through 2026 as positive clinical data accumulated. A minority Hold ratings and a wide target range signal that skepticism around execution and endpoint interpretation persists.
Roivant's trajectory is shaped less by traditional macro variables than by biotech-specific forces, though interest rates remain relevant. Lower long-term rates tend to support valuations of pre-profit, cash-rich developers, while a higher-rate environment raises the opportunity cost of holding unprofitable growth assets. Inflation in healthcare pricing and reimbursement dynamics will influence launch economics for LISRAYA.
The broader regulatory climate matters as well: the FDA's Breakthrough Therapy designation for brepocitinib in cutaneous sarcoidosis and the Priority Review pathway for dermatomyositis illustrate a collaborative regulatory posture that could accelerate timelines. Competitive dynamics in the FcRn inhibitor class and the pulmonary hypertension space will determine pricing and share. Meanwhile, the resolution of intellectual-property litigation with Moderna, including the $2.25 billion settlement, removes a layer of legal overhang while adding non-dilutive capital.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is designed to help users identify developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking ROIV, tools like the Trend Prediction Engine can complement fundamental analysis by highlighting short-term directional signals.
Looking toward 2026 and beyond, Roivant's medium-term story hinges on converting a promising pipeline into sustainable commercial revenue. The successful launch of LISRAYA would establish the company's commercial infrastructure and provide a template for subsequent product introductions. Success in non-infectious uveitis and cutaneous sarcoidosis would extend brepocitinib's franchise, while IMVT-1402's data in Graves' disease, expected in 2027, represents a major long-term catalyst given the estimated hundreds of thousands of uncontrolled U.S. patients.
Margin sustainability will depend on pricing strategy and reimbursement access, while cost structure will evolve as the company invests in commercial and manufacturing capabilities. Competitive threats from established players in immunology and pulmonary hypertension could compress potential peak sales, and regulatory feedback on trial designs will shape future capital allocation. Consensus expectations currently imply meaningful upside from current levels, with the average price target near $49.64, but those figures reflect external analyst assumptions rather than guaranteed outcomes. Investors will likely focus on execution quality, data durability, and the pace of label expansion as the defining themes of the next several years.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To ROIV | 1D Price Change % | ||
|---|---|---|---|---|
| ROIV | 100% | -0.78% | ||
| IMVT - ROIV | 66% Loosely correlated | -2.31% | ||
| COGT - ROIV | 47% Loosely correlated | -3.70% | ||
| IMTX - ROIV | 46% Loosely correlated | -3.03% | ||
| MLYS - ROIV | 44% Loosely correlated | -3.53% | ||
| DNTH - ROIV | 44% Loosely correlated | -0.33% | ||
More | ||||
Industry Biotechnology
The 10-day moving average for ROIV crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
ROIV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ROIV advanced for three days, in 232 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 187 of 239 cases where ROIV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The 10-day RSI Indicator for ROIV moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 30 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 57 cases where ROIV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ROIV as a result. In 73 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for ROIV turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 40 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ROIV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ROIV broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.637) is normal, around the industry mean (3.596). ROIV has a moderately low P/E Ratio (-108.000) as compared to the industry average of (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. ROIV's P/S Ratio (3333.333) is slightly higher than the industry average of (443.347).
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.